Driehaus Capital Management LLC Morphic Holding, Inc. Transaction History

Driehaus Capital Management LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$19.95 - $31.0 $53,047 - $82,429	-2,659 Reduced 1.91%	136,465 $3.94 Million
Q3 2023 Nov 14, 2023	SELL	$21.33 - $59.42 $9.21 Million - $25.7 Million	-431,932 Reduced 75.64%	139,124 $3.19 Million
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $9.13 Million - $16.5 Million	265,818 Added 87.09%	571,056 $32.7 Million
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $4.81 Million - $9.01 Million	185,050 Added 153.97%	305,238 $11.5 Million
Q4 2022 Feb 14, 2023	SELL	$24.14 - $30.37 $38,744 - $48,743	-1,605 Reduced 1.32%	120,188 $3.22 Million

Q3 2022 Nov 14, 2022	SELL	$22.23 - $33.37 $69,246 - $103,947	-3,115 Reduced 2.49%	121,793 $3.45 Million
Q2 2022 Aug 15, 2022	SELL	$19.74 - $43.01 $5.1 Million - $11.1 Million	-258,609 Reduced 67.43%	124,908 $2.71 Million
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $4.82 Million - $6.92 Million	-132,956 Reduced 25.74%	383,517 $15.4 Million
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $2.33 Million - $3.54 Million	53,802 Added 11.63%	516,473 $24.5 Million
Q3 2021 Nov 15, 2021	BUY	$53.61 - $67.5 $2.63 Million - $3.31 Million	49,082 Added 11.87%	462,671 $26.2 Million
Q2 2021 Aug 16, 2021	BUY	$45.13 - $64.99 $9.4 Million - $13.5 Million	208,352 Added 101.52%	413,589 $23.7 Million
Q1 2021 May 17, 2021	BUY	$29.77 - $84.85 $4.99 Million - $14.2 Million	167,737 Added 447.3%	205,237 $13 Million
Q4 2020 Feb 16, 2021	BUY	$25.66 - $34.55 $962,250 - $1.3 Million	37,500 New	37,500 $1.26 Million

142

37.9M

13.5K

190K

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $1.31B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.